CVE-2023-42666 — MEDIUM (5.3)

Vulnerability Description

The affected product is vulnerable to an exposure of sensitive information to an unauthorized actor vulnerability, which may allow an attacker to create malicious requests for obtaining the information of the version about the web server used.

CVSS Score

5.3

MEDIUM

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N

Attack Vector

NETWORK

Attack Complexity

LOW

Privileges Required

NONE

User Interaction

NONE

Scope

UNCHANGED

Confidentiality

LOW

Integrity

NONE

Availability

NONE

Affected Products

Vendor	Product	Versions
Dexma	Dexgate	20130114

Related Weaknesses (CWE)

CWE-200

References

https://www.cisa.gov/news-events/ics-advisories/icsa-23-271-02Third Party AdvisoryUS Government Resource
https://www.cisa.gov/news-events/ics-advisories/icsa-23-271-02Third Party AdvisoryUS Government Resource

FAQ

What is CVE-2023-42666?

CVE-2023-42666 is a vulnerability with a CVSS score of 5.3 (MEDIUM). The affected product is vulnerable to an exposure of sensitive information to an unauthorized actor vulnerability, which may allow an attacker to create malicious requests for obtaining t...

How severe is CVE-2023-42666?

CVE-2023-42666 has been rated MEDIUM with a CVSS base score of 5.3/10. Review the CVSS metrics above for detailed severity breakdown.

Is there a patch for CVE-2023-42666?

Check the references section above for vendor advisories and patch information. Affected products include: Dexma Dexgate.